' x='0' y='0' width='795' height='447'%3E%3C/rect%3E%3Ctext id='Loading-Preview' font-family='AvenirNext-Bold, Avenir Next' font-size='42' font-weight='bold' fill='%23FFFFFF'%3E%3Ctspan x='228.715' y='211'%3ELoading Preview%3C/tspan%3E%3C/text%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Description | Access more information about PLUVICTO for patients with PSMA+ metastatic castration-resistant prostate cancer (mCRPC) previously treated with ARPI and taxane therapies. See full prescribing & safety information. |
h1 tags | Interest-Based Ads After hormone therapy, men with PSMA+ mCRPC who received PLUVICTO saw: Interested in receiving information about PLUVICTO? |
h2 tags | Important Safety Information Approved Use |
Site Speed | 0.15254616737366 |
Alexa Rank: |
0 |
Site's Traffic |
|
| Host | Type | Class | TTL | Target |
| us.pluvicto.com | A | IN | 21600 | |
| us.pluvicto.com | A | IN | 21600 | |
| us.pluvicto.com | TXT | IN | 21600 |